Activin subunit and receptor expression in normal and cleft human fetal palate tissues

Pediatric and Developmental Pathology

Volumn 10, Issue 6, 2007, Pages 436-445

  Lambert Messerlian, Geralyn ^a   Eklund, Elizabeth ^a   Pinar, Haut ^a   Tantravahi, Umadevi ^a   Schneyer, Alan L ^b  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Activin; Cleft; Palate

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 2; FOLLISTATIN; INHIBIN; INHIBIN A; INHIBIN B; MESSENGER RNA; MYELOPID;

ARTICLE; AUTOPSY; BONE CELL; BONE DEVELOPMENT; CLEFT PALATE; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPMENT; GENE EXPRESSION; GESTATION PERIOD; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; PALATE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE HOMOGENATE;

ACTIVIN RECEPTORS, TYPE II; CLEFT PALATE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLISTATIN; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GESTATIONAL AGE; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBIN-BETA SUBUNITS; PALATE; RNA, MESSENGER;

EID: 37349025741     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/06-05-0087.1     Document Type: Article

References (37)

1. Tolarova MM, Cervenka J. Classification and birth prevalence of orofacial clefts. Am J Med Genet 1998;75:126-137.
2. Perkins JA, Sie KC, Milczuk H, Richardson MA. Airway management in children with craniofacial anomalies. Cleft Palate-Craniofac J, 1997;34:135-140.
3. Carinci F, Pezzetti F, Scapoli L, et al. Recent developments in orofacial cleft genetics. J Craniofac Surg 2003;14:130-143.
4. Roberts VJ, Sawchenko PE, Vale W. Expression of inhibin/activin subunit messenger ribonucleic acids during rat embryogenesis. Endocrinology 1991;128:3122-3129.
5. Feijen A, Goumans MJ, van den Eijnden-Van Raaij AJM. Expression of activin subunits, activin receptors and follistatin in postimplantation mouse embryos suggests specific developmental functions for different activins. Development 1994;120:3621-3637.
6. Cook RW, Thompson TB, Kurup SP, Jardetzky TS, Woodruff TK. Structural basis for a functional antagonist in the transforming growth factor B superfamily. J Biol Chem 2005;280:40177-40186.
7. Roberts VJ, Barth SL. Expression of messenger ribonucleic acids encoding the inhibin/activin system during mid- and late-gestation rat embryogenesis. Endocrinology 1994;134:914-923.
8. Matzuk MM, Kumar TR, Vassalli A, et al. Functional analysis of activins during mammalian development. Nature 1995;374:354-356.
9. Ferguson CA, Tucker AS, Christensen L, Lau AL, Matzuk MM, Sharpe PT. Activin is an essential early mesenchymal signal in tooth development that is required for patterning of the murine dentition. Genes and Dev 1998;12:2636-2649.
10. Matzuk MM, Kumar TR, Bradley A. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature 1995;374:356-360.
11. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal death in mice deficient in follistatin. Nature 1995;374:360-363.
12. Spencer SJ, Rabinovici J, Mesiano S, Goldsmith PC, Jaffe RB. Activin and inhibin in the human adrenal gland. Regulation and differential effects in fetal and adult cells. J Clin Invest 1992;90:142-149.
13. Majdic G, McNeilly AS, Sharpe RM, Evans LR, Groome NP, Saunders PT. Testicular expression of inhibin and activin subunits and follistatin in the rat and human fetus and neonate and during postnatal development in the rat. Endocrinology 1997;138:2136-2147.
14. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF Jr, Schneyer AL. Presence of activin, inhibin and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 1997;82:3720-3727.
15. -delta delta C(T)) method. Methods 2001;25:402-408.
16. A dimer) during human pregnancy. Clin Endocrinol (Oxf) 1995;42:391-397.
17. Muttukrishna S, Fowler PA, George L, Groome NP, Knight PG. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab 1996;81:3328-3334.
18. Wada M, Shintani Y, Kosaka M, Sano T, Hizawa K, Saito S. Immunohistochemical localization of activin A and follistatin in human tissues. Endocr J 1996;43:375-385.
19. Gu K, Smoke RH, Rutherford RB. Expression of genes for bone morphogenetic proteins and receptors in human dental pulp. Arch Oral Biol 1996;41:919-923.
20. Tuuri T, Eramaa M, Hilden K, Ritvos O. The tissue distribution of activin BA- and BB-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development. J Clin Endocrinol Metab 1994;78:1521-1524.
21. Harkness LM, Baird DT. Morphological and molecular characteristics of living human fetuses between Carnegie stages 7 and 23: immunolocalization of inhibin alpha and beta a subunits. Hum Reprod Update 1997;3:35-57.
22. Harkness LM, Baird DT. Morphological and molecular characteristics of living human fetuses between Carnegie stages 7 and 23: localization of inhibin mRNA a and beta a subunits by in situ hybridization. Hum Reprod Update 1997;3:59-92.
23. Centrella M, McCarthy TL, Canalis E. Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone. Molec Cell Biol 1991;11:250-258.
24. Fuller K, Bayley KE, Chambers TJ. Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 2000;5:2-7.
25. Hosoi T, Inoue S, Hoshino S, Ouchi Y, Orimo H. Immunohistochemical detection of activin A in osteoclasts. Gerontology 1996;42:20-24.
26. Shuto T, Sarkar G, Bronk JT, Matsui N, Bolander ME. Osteoblasts express type I and II activin receptors during early intermembranous and endochondral bone formation. J Bone Miner Res 1997;12:403-411.
27. Sakai R, Eto Y, Ohtsuka M, Hirafuji M, Shinoda H. Activin enhances osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 1993;195:39-46.
28. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 2002;143:74-83.
29. Murase Y, Okahashi N, Koseki T, Itoh K, Udagawa N, Hashimoto O, Sugino H, Noguchi T, Nishihara T. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A. J Cell Physiol 2001;188:236-242.
30. Funaba M, Ogawa K, Murata T, et al. Follistatin and activin in bone: expression and localization during endochondral bone development. Endocrinology 1996;137:4250-4259.
31. Inoue S, Nomura S, Hosoi T, Ouchi Y, Orimo H, Muramatsu M. Localization of follistatin, an activin-binding protein, in bone tissues. Calcif Tissue Int 1994;55:395-397.
32. Abe Y, Abe T, Aida Y, Hara Y, Maeda K. Follistatin restricts bone morphogenetic protein (BMP)-2 action on the differentiation of osteoblasts in fetal rat mandibular cells. J Bone Miner Res 2004;19:1302-1307.
33. Sperber GH. Formation of the Primary Palate. In: DF Wyszynski, ed. Cleft Lip and Palate. New York: Oxford University Press, 2002;5-14.
34. Lambert-Messerlian GM, Pinar H, Laprade E, Tantravahi U, Schneyer A, Canick JA. Inhibins and Activins in Human Fetal Abnormalities. In: I Huhtaniemi, W Rainey, R Rodgers, JE Dumont, TK Woodruff, eds. Molecular and Cellular Endocrinology. Oxford, UK: Elsevier Ireland Ltd, 2004;225(1-2):101-108.
35. Taya Y, O'Kane S, Ferguson MW. Pathogenesis of cleft palate in TGF-beta3 knockout mice. Development 1999;126:3869-3879.
36. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275-281.
37. Dudas M, Nagy A, Laping NJ, Moustakas A, Kaartinen V. Tgf-B3-induced palatal fusion is mediated by Alk-5/Smad pathway. Dev Biol 2004;266:96-108.